Larvol Delta - OpenLabel-SingleArm-Phase-IbIi-Study-of-Immune-Combination-Therapy-with-Belantamab-Mafodotin-and-Elotuzumab-in-Patients-with-RelapsedRefractory-Multiple-Myeloma-RRMM

Blenrep (belantamab mafodotin-blmf) - GSK

Empliciti (elotuzumab) - AbbVie, BMS

https://imsannual2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=TU1XRFNPTlIyMjY0Nw&PosterID=826773&rnd=0.9399711

Natalia Neparidze, MD

Sep 11, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next